Abstract
The introduction of interferon-β1b (IFN-β1b, Betaseron) in 1993 heralded a new era in the management of multiple sclerosis (MS). A modest overall reduction of exacerbations of 33.8% was enhanced by a 47% reduction for “moderately severe and severe exacerbations”, as defined in the protocol [1]. Adverse experience with IFN-β1b, however, was encountered in the majority of trial participants, as well as in the clinical setting [1, 2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661
Report of the Quality Standards Subcommittee of the AAN (1994) Neurology 44:1537–1540
Sheremata WA, Taylor A, Elgart GW (1995) Severe necrotizing cutaneous lesions complicating interferon-beta-lb: clinical features and biopsy results. N Engl J Med 332:23
Elgart GW, Sheremata WA, Ahn YS (1997) Cutaneous reactions to recombinant interferon-beta-lb: the clinical and histologic spectrum. J Am Acad Dermatol 37:553–558
Paty DW, Hartung HP, Ebers GC et al (1999) Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur Neurol 6 [Suppl 1]:S1–S35
Di Paola M, Ogin E, Smith Y et al (1992) Interferon-a subtypes in natural human leukocyte interferon (interferonα-n3). J Interferon Res 12:5318
Squillacote D, Martinez M, Sheremata WA (1996) Natural alpha interferon in multiple sclerosis: preliminary results and follow-up. J Int Med Res 24:246–257
Sheremata W, Minagar A, Whiteman M, Onufer J (2001) Interferon-alfa-n3 (Alferon N) reduces gadolinium enhancing brain lesions in multiple sclerosis. J Neurosci 187 [Suppl 1] S454
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Italia
About this chapter
Cite this chapter
Sheremata, W.A., Minagar, A. (2004). Management of Interferon-β1b (Betaseron) Failures in Multiple Sclerosis with Interferon-αn3 (Alferon N). In: Hommes, O.R., Comi, G. (eds) Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-2117-4_20
Download citation
DOI: https://doi.org/10.1007/978-88-470-2117-4_20
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2171-6
Online ISBN: 978-88-470-2117-4
eBook Packages: Springer Book Archive